Abstract
Background: Immune checkpoint inhibitors exhibit efficacy for only 15% all colorectal cancer (CRC) patients. Therefore, gaining a further understanding of the immunosuppressive mechanism in CRC is necessary. To this end, we studied immunological changes during the peritoneal tumor growth of CRC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical oncology (Royal College of Radiologists (Great Britain))
Paper Title
Journal
Date
